Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336855 | 0.87 | TSHR (0.49) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3052776 | 0.84 | TSHR (0.59) | MMP13CNR2MEN1KMT2AKDM4E | |
| SCHEMBL1336955 | 0.83 | BCL2A1 (0.49) | CNR2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL1335750 | 0.83 | MAPK14 (0.54) | ALDH1A1MEN1KMT2AKDM4ECYP2C19 | |
| SCHEMBL4237595 | 0.82 | CNR2 (0.58) | CNR2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL1337080 | 0.82 | USP2 (0.60) | ALDH1A1MEN1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL1336917 | 0.81 | SMN1; SMN2 (0.46) | MMP13MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL3054221 | 0.81 | TSHR (0.59) | MMP13CNR2MEN1KMT2AKDM4E | |
| SCHEMBL2717555 | 0.78 | GAA (0.67) | ALDH1A1MEN1KMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL1336094 | 0.78 | TSPO (0.46) | MMP13ALDH1A1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | claimed |
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | GPR119, GLP1R, ADIPOR1 | MMP13 4099/4885CNR2 113/4885ALDH1A1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.